Eli Lilly has signed on to collaborate on fruquintinib, committing to a package of $86.5 million in fees and milestones to partner on a tumor treatment which was put up on the deal table earlier this year.
CardioKinetix hit another big milestone recently with news that the California company's heart failure treatment device has been successfully implanted into two patients in China. Asia is a pivotal part of the world for medical device companies right now, and China is the brass ring.
Catalent has snapped up a Brazilian contract manufacturer, expanding its hold on the global softgel market by growing its presence in Latin America.
Noting that Japan is one of the world's fastest-growing pharmaceutical markets, Marc Dunoyer, AstraZeneca's executive vice president of global products and portfolio strategy said: "This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers."
It seemed like a match made in heaven. A few years ago, as the patent cliff neared and drugmakers were looking for new sources of revenue, market researchers were toting up growth prospects around...
The emergence of Indian vaccine manufacturers has helped health authorities drive down the cost of immunization campaigns. Now, the downwards trend is set to accelerate. China has entered the global vaccine arena.
Medtronic will link with Apollo Hospitals Enterprise--one of India's largest healthcare providers--to develop a portable kidney dialysis system. The project represents the Minnesota device giant's first foray into hemodialysis and yet another diversification move for the company.
Drugmakers weren't exactly thrilled last year when Indian ministers nearly quintupled the list of drugs subject to government price controls. As it turns out, neither were bulk buyers of those products. GlaxoSmithKline is now feeling the effects of their discontent, with buyers' protests reportedly hurting the British drugmaker's sales.
Late-phase data has tempered expectations for GlaxoSmithKline's malaria vaccine. Yet while the vaccine prevents fewer cases than hoped and immunity wanes, it still has the potential to cut incidence of disease. Glaxo is readying for a regulatory submission. A malaria vaccine could arrive in 2015.
Syngene, the CRO arm of Indian biotech giant Biocon, is poised to swell about 20% a year, CEO Kiran Mazumdar-Shaw said, making it the continent's fastest-growing service provider.